Search
Vicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesNorelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalNorelgestromin is a progestin used as the progestational component of combined hormonal contraceptives. It is administered transdermally in combination with the estrogen ethinyl estradiol, delivering both hormones systemically over a 7-d...
Synonyms: D-Norgestrel 3-oximeCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesHalcinonide
go.drugbank.com/drugs/DB06786ApprovedWithdrawnHalcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Ha...
Synonyms: (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS)-6b-(chloroacetyl)-4b-fluoro-5-hydroxy-4a,6a,8,8-tetramethyl-3,4,4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-tetradecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-oneCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAzilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAzilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relativ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEllagic acid
go.drugbank.com/drugs/DB08846InvestigationalEllagic acid is present in several fruits such as cranberries, strawberries, raspberries, and pomegranates. In pomegranates, there are several therapeutic compounds but ellagic acid is the most active and abundant. Ellagic acid is also p...
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme InhibitorsCabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSuvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesVortioxetine
go.drugbank.com/drugs/DB09068ApprovedInvestigationalVortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesLenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalLenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates